Please try another search
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Name | Age | Since | Title |
---|---|---|---|
Carl S. Goldfischer | 64 | 2016 | Independent Director |
Edward R. Conner | 50 | 2020 | Independent Director |
Barbara J. Dalton | 70 | 2016 | Independent Director |
David M. Mott | 58 | 2016 | Independent Chairman |
Kim Andersen | - | 2016 | Board Observer |
Joel S. Marcus | 76 | - | Board Observer |
Laura A. Williams | 60 | 2021 | Independent Director |
Matthew Hammond | 34 | 2019 | Board Observer |
John Cassidy | - | 2019 | Board Observer |
Rahul D. Ballal | 45 | 2018 | President, CEO & Director |
Mark Chin | 40 | 2019 | Independent Director |
David Bonita | 47 | 2019 | Independent Director |
Samuel S. Kintz | - | - | Co-Founder, CEO, Secretary & Director |
Jake B. Bauer | 44 | 2021 | Independent Director |
Richard A. Heyman | 66 | 2021 | Independent Chairman |
Andrew J. Phillips | 52 | 2020 | Independent Director |
Rishi Gupta | 46 | 2019 | Independent Director |
Rahul D. Ballal | 45 | 2018 | Director |
Mika Kakefuda Derynck | 60 | 2021 | Independent Director |
Lori Anne Kunkel | 66 | 2024 | Independent Director |
Joseph P. Lyssikatos | 59 | 2019 | Co-Founder, Chief Scientific Officer & Directors |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review